# Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions

> **NCT06199791** · PHASE1 · COMPLETED · sponsor: **Desitin Arzneimittel GmbH** · enrollment: 24 (actual)

## Conditions studied

- Fasting

## Interventions

- **DRUG:** Lamotrigine 100 MG

## Key facts

- **NCT ID:** NCT06199791
- **Lead sponsor:** Desitin Arzneimittel GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-03
- **Primary completion:** 2023-05-09
- **Final completion:** 2023-06-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06199791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06199791, "Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06199791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*